KUBÍČEK, Luboš, Radek VITASEK, David SCHWARZ, Robert STAFFA, Petr STRAKOS and Stanislav POLZER. Biomechanical Rupture Risk Assessment in Management of Patients with Abdominal Aortic Aneurysm in COVID-19 Pandemic. Diagnostics. Basel: MDPI, 2023, vol. 13, No 1, p. 1-12. ISSN 2075-4418. Available from: https://dx.doi.org/10.3390/diagnostics13010132.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Biomechanical Rupture Risk Assessment in Management of Patients with Abdominal Aortic Aneurysm in COVID-19 Pandemic
Authors KUBÍČEK, Luboš (203 Czech Republic, guarantor, belonging to the institution), Radek VITASEK (203 Czech Republic), David SCHWARZ (203 Czech Republic), Robert STAFFA (203 Czech Republic, belonging to the institution), Petr STRAKOS (203 Czech Republic) and Stanislav POLZER (203 Czech Republic).
Edition Diagnostics, Basel, MDPI, 2023, 2075-4418.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30212 Surgery
Country of publisher Sweden
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 3.600 in 2022
RIV identification code RIV/00216224:14110/23:00130353
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.3390/diagnostics13010132
UT WoS 000909283300001
Keywords in English abdominal aortic aneurysm; biomechanics; rupture risk; predictability; COVID-19
Tags 14110121, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 19/2/2024 15:23.
Abstract
Background: The acute phase of the COVID-19 pandemic requires a redefinition of healthcare system to increase the number of available intensive care units for COVID-19 patients. This leads to the postponement of elective surgeries including the treatment of abdominal aortic aneurysm (AAA). The probabilistic rupture risk index (PRRI) recently showed its advantage over the diameter criterion in AAA rupture risk assessment. Its major improvement is in increased specificity and yet has the same sensitivity as the maximal diameter criterion. The objective of this study was to test the clinical applicability of the PRRI method in a quasi-prospective patient cohort study. Methods: Nineteen patients (fourteen males, five females) with intact AAA who were postponed due to COVID-19 pandemic were included in this study. The PRRI was calculated at the baseline via finite element method models. If a case was diagnosed as high risk (PRRI > 3%), the patient was offered priority in AAA intervention. Cases were followed until 10 September 2021 and a number of false positive and false negative cases were recorded. Results: Each case was assessed within 3 days. Priority in intervention was offered to two patients with high PRRI. There were four false positive cases and no false negative cases classified by PRRI. In three cases, the follow-up was very short to reach any conclusion. Conclusions: Integrating PRRI into clinical workflow is possible. Longitudinal validation of PRRI did not fail and may significantly decrease the false positive rate in AAA treatment.
PrintDisplayed: 6/7/2024 07:59